Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (20048)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 21, 2020 (publication date) through Nov 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v26/i39/5919.htm |
| Number | Citing Articles |
| 1 |
Muhammad Radzi Abu Hassan, Rosaida Hj Md Said, Zalwani Zainuddin, Haniza Omar, Siti Maisarah Md Ali, Siti Aishah Aris, Huan-Keat Chan. Effects of one-year supplementation with Phyllanthus niruri on fibrosis score and metabolic markers in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Heliyon 2023; 9(6): e16652 doi: 10.1016/j.heliyon.2023.e16652
|
| 2 |
Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin. Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities,
and Management of Non-alcoholic Fatty Liver Disorder. Current Drug Therapy 2024; 19(1): 20 doi: 10.2174/1574885518666230417111247
|
| 3 |
Cheng Han Ng, Kai En Chan, Mark Muthiah, Caitlyn Tan, Phoebe Tay, Wen Hui Lim, Darren Jun Hao Tan, Clarissa Elysia Fu, Jie Ning Yong, Zhen Yu Wong, Benjamin Koh, Nicholas WS Chew, Nicholas Syn, Daniel Q. Huang, Yock Young Dan, Mohammad S. Siddiqui, Arun J. Sanyal, Mazen Noureddin. Examining the interim proposal for name change to steatotic liver disease in the US population. Hepatology 2023; 77(5): 1712 doi: 10.1097/HEP.0000000000000043
|
| 4 |
Yuling Song, Boru Chen, Lu Jiang, Fangkun Zhao, Xiuqin Feng. Global Trends of Treatment for NAFLD from 2012 to 2021: A Bibliometric
and Mapping Analysis. Endocrine, Metabolic & Immune Disorders - Drug Targets 2024; 24(5): 573 doi: 10.2174/0118715303230418230925060312
|
| 5 |
Ranyang Liu, Linlin Feng, Shuang Tang, Yin Liu, Qin Yang.
The Impact and Mechanism of
TET3
Overexpression on the Progression of Hepatic Fibrosis
. Epigenomics 2023; 15(10): 577 doi: 10.2217/epi-2023-0146
|
| 6 |
Jonathan Mertens, Luc F. Van Gaal, Sven M. Francque, Christophe De Block. NAFLD in type 1 diabetes: overrated or underappreciated?. Therapeutic Advances in Endocrinology and Metabolism 2021; 12 doi: 10.1177/20420188211055557
|
| 7 |
Jörn M Schattenberg, Quentin M Anstee, Cyrielle Caussy, Elisabetta Bugianesi, Branko Popovic. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Review of Gastroenterology & Hepatology 2021; 15(11): 1253 doi: 10.1080/17474124.2021.1974295
|
| 8 |
An Zhang, Xin Luo, Hong Pan, Xinxin Shen, Baocheng Liu, Dong Li, Jijia Sun. Establishment and evaluation of a risk-prediction model for hypertension in elderly patients with NAFLD from a health management perspective. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-18718-3
|
| 9 |
燕凤 王. Research Progress on the Mechanism of Lipid Metabolism in the Occurrence and Development of Cirrhosis. Traditional Chinese Medicine 2024; 13(06): 1171 doi: 10.12677/tcm.2024.136177
|
| 10 |
Gang Chen, Jun-cheng Yang, Gui-xiang Zhang, Zhong Cheng, Xiao Du. Evaluation of Six Noninvasive Methods for the Detection of Fibrosis in Chinese Patients with Obesity and Nonalcoholic Fatty Liver Disease. Obesity Surgery 2022; 32(11): 3619 doi: 10.1007/s11695-022-06251-1
|
| 11 |
Laura Valenzuela-Vallejo, Despina Sanoudou, Christos S. Mantzoros. Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease. Journal of Personalized Medicine 2023; 13(5): 830 doi: 10.3390/jpm13050830
|
| 12 |
Mohamed Abdel-Samiee, Essam Salah Ibrahim, Mohamed Kohla, Eman Abdelsameea, Mohsen Salama. Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis. World Journal of Gastrointestinal Pharmacology and Therapeutics 2024; 15(6): 97381 doi: 10.4292/wjgpt.v15.i6.97381
|
| 13 |
Bangjie Li, Jialiang Hu, Hanmei Xu. Integrated single-cell and bulk RNA sequencing reveals immune-related SPP1+ macrophages as a potential strategy for predicting the prognosis and treatment of liver fibrosis and hepatocellular carcinoma. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1455383
|
| 14 |
Sung-Bum Lee, Yu-Jin Kwon, Dong-Hyuk Jung, Jong-Koo Kim. Association of Muscle Strength with Non-Alcoholic Fatty Liver Disease in Korean Adults. International Journal of Environmental Research and Public Health 2022; 19(3): 1675 doi: 10.3390/ijerph19031675
|
| 15 |
Alejandro Campos-Murguía, Berenice M Román-Calleja, José A González-Regueiro, Ivonne Hurtado-Díaz-de-León, Alberto Adrián Solís-Ortega, Nayelli C Flores-García, Ignacio García-Juárez, Astrid Ruiz-Margáin, Ricardo Ulises Macías-Rodríguez. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World Journal of Gastroenterology 2021; 27(33): 5502-5519 doi: 10.3748/wjg.v27.i33.5502
|
| 16 |
Gabriel De la Cruz-Ku, Alba Zevallos, César Ramón Rázuri-Bustamante, Sasank Kalipatnapu, Fortunato S. Príncipe-Meneses, Paola Dongo, Diego Chambergo-Michilot, Gustavo Salinas-Sedo, Bryan Valcarcel. Predictors of Nonalcoholic Steatohepatitis Severity in Obese Patients Undergoing Bariatric Surgery: A Cross-Sectional Study. Bariatric Surgical Practice and Patient Care 2023; 18(4): 218 doi: 10.1089/bari.2022.0043
|
| 17 |
Qiang Chen, Yifeng Lou. G protein-coupled receptor 39 alleviates mitochondrial dysfunction and hepatocyte lipid accumulation via SIRT1/Nrf2 signaling. Journal of Bioenergetics and Biomembranes 2023; 55(1): 33 doi: 10.1007/s10863-022-09953-4
|
| 18 |
Xiang-Yan Liu, Jian-Fang Lu, Li-Dong Wang, Zhuo-Yi Wang. Diagnostic value of shear wave velocity measured by virtual touch tissue imaging quantification combined with hepatic blood flow index measured by single-photon emission computed tomography first-pass method for hepatitis B fibrosis. World Chinese Journal of Digestology 2023; 31(12): 492 doi: 10.11569/wcjd.v31.i12.492
|
| 19 |
Ritanna Curci, Antonella Bianco, Isabella Franco, Caterina Bonfiglio, Angelo Campanella, Antonella Mirizzi, Vito Giannuzzi, Raffaele Cozzolongo, Nicola Veronese, Alberto Ruben Osella. Lifestyle Modification: Evaluation of the Effects of Physical Activity and Low-Glycemic-Index Mediterranean Diet on Fibrosis Score. Nutrients 2023; 15(16): 3520 doi: 10.3390/nu15163520
|
| 20 |
Tracy Bonsu Osei, Anne-Marieke van Dijk, Sjoerd Dingerink, Felix Patience Chilunga, Erik Beune, Karlijn Anna Catharina Meeks, Silver Bahendeka, Matthias Bernd Schulze, Charles Agyemang, Mary Nicolaou, Adriaan Georgius Holleboom, Ina Danquah. Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study. Nutrients 2021; 13(11): 3679 doi: 10.3390/nu13113679
|
| 21 |
Zheng Xu, Fan-Wei Wu, Xuan Niu, Xiao-Peng Lu, Yan-Rong Li, Shu-Ting Zhang, Jun-Zhao Ou, Xue-Mei Wang. Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease. Pharmaceutical Biology 2022; 60(1): 1819 doi: 10.1080/13880209.2022.2106250
|
| 22 |
D. V. Garbuzenko. Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2022; 31(5): 16 doi: 10.22416/1382-4376-2021-31-5-16-24
|
| 23 |
Zahra Tolou-Ghamari, Abbas-Ali Palizban. Biomarkers, Biocatalysts, or Pathology Conditions to Evaluate Potential History of Liver Disease such as Cancer. Clinical Cancer Investigation Journal 2022; 11(6): 31 doi: 10.51847/caGjAHyB9E
|
| 24 |
Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha. Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease. Cureus 2023; doi: 10.7759/cureus.43635
|
| 25 |
Xi Le, Yin Zhang, Mei Yang, Jie Li, Hao Wang, Jin-Lin Wu, Juan Deng, Hong-Min Zhang. Effect of <i>Dendrobium nobile</i> powder combined with conventional therapy on mild to moderate fatty liver. World Journal of Gastroenterology 2024; 30(45): 4791-4800 doi: 10.3748/wjg.v30.i45.4791
|
| 26 |
D.V. Garbuzenko. Non-invasive diagnosis of liver fibrosis associated with nonalcoholic steatohepatitis. Dokazatel'naya gastroenterologiya 2021; 10(4): 75 doi: 10.17116/dokgastro20211004175
|
| 27 |
Fangbin Liu, Shengnan Li, Panpan Chen, Yanqiu Gu, Shaozhan Wang, Lei Wang, Chun Chen, Rong Wang, Yongfang Yuan. Salvianolic acid B inhibits hepatic stellate cell activation and liver fibrosis by targeting PDGFRβ. International Immunopharmacology 2023; 122: 110550 doi: 10.1016/j.intimp.2023.110550
|
| 28 |
Kaelee S. Brockway, Leslie Ayres, Michael J. Shoemaker. Putting It All Together: An Evidence-Based Guide to High-Intensity Interval Exercise Prescription for Patients With Complex Comorbidities. Cardiopulmonary Physical Therapy Journal 2023; 34(4): 152 doi: 10.1097/CPT.0000000000000224
|
| 29 |
Fei Meng, Qin Wu, Wei Zhang, Shirong Hou. Application of Interpretable Machine Learning Models Based on Ultrasonic Radiomics for Predicting the Risk of Fibrosis Progression in Diabetic Patients with Nonalcoholic Fatty Liver Disease. Diabetes, Metabolic Syndrome and Obesity 2023; : 3901 doi: 10.2147/DMSO.S439127
|
| 30 |
Siarhei A. Dabravolski, Evgeny E. Bezsonov, Mirza S. Baig, Tatyana V. Popkova, Ludmila V. Nedosugova, Antonina V. Starodubova, Alexander N. Orekhov. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. International Journal of Molecular Sciences 2021; 22(9): 4459 doi: 10.3390/ijms22094459
|
| 31 |
Yacong Xiao, Xiujuan Li, Li Wang, Mingyue Hu, Youlin Liu. Proanthocyanidin A2 attenuates the activation of hepatic stellate cells by activating the PPAR-γ signalling pathway. Autoimmunity 2023; 56(1) doi: 10.1080/08916934.2023.2250101
|
| 32 |
Rui Zhang, Quanwei Zhang, ZiYi Cui, BenZeng Huang, Haitian Ma. Dimethyl fumarate restores Ca2+ dyshomeostasis through activation of the SIRT1 signal to treat nonalcoholic fatty liver disease. Life Sciences 2024; 341: 122505 doi: 10.1016/j.lfs.2024.122505
|
| 33 |
Meiqi Fan, Young-Jin Choi, Yujiao Tang, Ji Hye Kim, Byung-gyu Kim, Bokyung Lee, Sung Mun Bae, Eun-Kyung Kim. AGL9: A Novel Hepatoprotective Peptide from the Larvae of Edible Insects Alleviates Obesity-Induced Hepatic Inflammation by Regulating AMPK/Nrf2 Signaling. Foods 2021; 10(9): 1973 doi: 10.3390/foods10091973
|
| 34 |
Farah Abdelhameed, Chris Kite, Lukasz Lagojda, Alexander Dallaway, Kamaljit Kaur Chatha, Surinderjeet S. Chaggar, Maria Dalamaga, Eva Kassi, Ioannis Kyrou, Harpal S. Randeva. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD. Current Obesity Reports 2024; 13(3): 510 doi: 10.1007/s13679-024-00574-z
|
| 35 |
María C. Brañes, Raimundo Gillet, Rodrigo Valenzuela. Efficacy of Submicron Dispersible Free Phytosterols on Non-Alcoholic Fatty Liver Disease: A Pilot Study. Journal of Clinical Medicine 2023; 12(3): 979 doi: 10.3390/jcm12030979
|
| 36 |
Anna Kleczka, Bogdan Mazur, Krzysztof Tomaszek, Andrzej Gabriel, Radosław Dzik, Agata Kabała-Dzik. Association of NK Cells with the Severity of Fibrosis in Patients with Chronic Hepatitis C. Diagnostics 2023; 13(13): 2187 doi: 10.3390/diagnostics13132187
|
| 37 |
Mingxi Chen, Chang Guo, Ke Ouyang, Na Liu. Diagnostic role of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score as a noninvasive tool for liver fibrosis scoring. Medicine 2024; 103(43): e40214 doi: 10.1097/MD.0000000000040214
|